MX2018012361A - Metodos de tratamiento con agonistas selectivos del receptor cb2. - Google Patents

Metodos de tratamiento con agonistas selectivos del receptor cb2.

Info

Publication number
MX2018012361A
MX2018012361A MX2018012361A MX2018012361A MX2018012361A MX 2018012361 A MX2018012361 A MX 2018012361A MX 2018012361 A MX2018012361 A MX 2018012361A MX 2018012361 A MX2018012361 A MX 2018012361A MX 2018012361 A MX2018012361 A MX 2018012361A
Authority
MX
Mexico
Prior art keywords
methods
treatment
selective
receptor agonists
receptor
Prior art date
Application number
MX2018012361A
Other languages
English (en)
Inventor
Shanahan William
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MX2018012361A publication Critical patent/MX2018012361A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan métodos para tratar un trastorno relacionado con el receptor CB2 (por ejemplo, dolor, fibrosis). Estos métodos están dirigidos a reducir el riesgo de efectos adversos en función de la presión arterial y/o frecuencia cardiaca reducidas en sujetos que necesitan tratamiento con un compuesto agonista del receptor CB2 (por ejemplo, APD371).
MX2018012361A 2016-04-10 2017-04-10 Metodos de tratamiento con agonistas selectivos del receptor cb2. MX2018012361A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662320572P 2016-04-10 2016-04-10
PCT/US2017/026848 WO2017180528A1 (en) 2016-04-10 2017-04-10 Methods of treatment with selective cb2 receptor agonists

Publications (1)

Publication Number Publication Date
MX2018012361A true MX2018012361A (es) 2019-05-30

Family

ID=60041951

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012361A MX2018012361A (es) 2016-04-10 2017-04-10 Metodos de tratamiento con agonistas selectivos del receptor cb2.

Country Status (13)

Country Link
US (1) US20190160058A1 (es)
EP (1) EP3452037A4 (es)
JP (1) JP2019510806A (es)
KR (1) KR20180128491A (es)
CN (1) CN109310673A (es)
AU (1) AU2017249211A1 (es)
BR (1) BR112018070786A2 (es)
CA (1) CA3019842A1 (es)
EA (1) EA201892280A1 (es)
IL (1) IL262135A (es)
MX (1) MX2018012361A (es)
UA (1) UA124626C2 (es)
WO (1) WO2017180528A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208847A1 (en) * 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
KR20200005614A (ko) * 2017-05-08 2020-01-15 아레나 파마슈티칼스, 인크. 내장 통증의 치료를 위한 화합물 및 방법
US11607275B2 (en) * 2019-05-20 2023-03-21 Medtronic Ireland Manufacturing Unlimited Company Selection of hypertensive patients for treatment with renal denervation
CA3212135A1 (en) * 2021-03-02 2022-09-09 Arena Pharmaceuticals, Inc. Methods of treatment with selective cb2 receptor agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605906A (en) * 1995-03-24 1997-02-25 Merck Frosst Canada, Inc. Cannabinoid receptor agonists
US7308894B2 (en) * 1998-06-03 2007-12-18 Scott Laboratories, Inc. Apparatuses and methods for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures according to appropriate clinical heuristics
WO2003063758A2 (en) * 2002-01-31 2003-08-07 Pharmos Corporation Bicyclic cb2 cannabinoid receptor ligands
IL150302A (en) * 2002-01-31 2008-07-08 Naim Menashe Bicyclic cb2 cannabinoid receptor ligands
US8044071B2 (en) * 2007-10-18 2011-10-25 Abbott Laboratories Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
CA2770866C (en) * 2009-08-28 2017-10-10 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
AU2012222149B2 (en) * 2011-02-25 2017-06-29 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EA035989B1 (ru) * 2011-02-25 2020-09-09 Арена Фармасьютикалз, Инк. Кристаллические формы и способы получения модуляторов каннабиноидного рецептора

Also Published As

Publication number Publication date
IL262135A (en) 2018-11-29
US20190160058A1 (en) 2019-05-30
EP3452037A4 (en) 2020-03-11
CN109310673A (zh) 2019-02-05
CA3019842A1 (en) 2017-10-19
BR112018070786A2 (pt) 2019-02-05
EP3452037A1 (en) 2019-03-13
KR20180128491A (ko) 2018-12-03
UA124626C2 (uk) 2021-10-20
AU2017249211A1 (en) 2018-11-22
JP2019510806A (ja) 2019-04-18
EA201892280A1 (ru) 2019-04-30
WO2017180528A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
MX2018012361A (es) Metodos de tratamiento con agonistas selectivos del receptor cb2.
MX2024004332A (es) Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos.
MY192917A (en) Compositions and methods of use for treating metabolic disorders
PH12017500680A1 (en) Compositions and methods of use for treating metabolic disorders
EA201992474A3 (ru) Агонисты 5ht для лечения нарушений
EP3773880A4 (en) Therapeutic modulation to treat blood glucose abnormalities, including type 2 diabetes, and/or reduce hba1c levels, and associated systems and methods
TW201613633A (en) Exendin-4 derivatives as selective glucagon receptor agonists
WO2017075607A8 (en) Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones
EA201891946A1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2020000713A (es) Metodos de aferesis y sus usos.
MX2018010863A (es) Tratamiento contra trastornos musculares con combinaciones de agonistas rxr y hormonas tiroideas.
MX2020000190A (es) Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco.
MX2016012219A (es) Agonistas de receptor fgf21 y usos del mismo.
LT3348547T (lt) Benzimidazolo dariniai, kaip nav 1.7 (nuo įtampos priklausančio natrio kanalo ix tipo alfa subvieneto (scn9a)) inhibitoriai, skirti skausmui, dizurijai ir išsėtinei sklerozei gydyti
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2020002741A (es) Uso de gaboxadol en el tratamiento de narcolepsia.
MX366685B (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
EP3765126C0 (en) DEVICE, KIT AND METHOD FOR PRODUCING A MEDICALLY ADMINISTERABLE INTRAVENOUS SALINE SOLUTION
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
MX2016003525A (es) Agentes dirigidos contra una interaccion cis de molecula de orientacion repulsiva a (rgma) /neogenina o balsas lipidicas y uso de los mismos en metodos de tratamiento.
BR112019024875A2 (pt) Métodos para o tratamento da ileíte do reservatório crônica
TN2017000517A1 (en) MULTl-PEPTIDE COMPOSITION
UA123387U (uk) Спосіб лікування хронічного суглобового болю